Current Edition

RE-MODELLING-DRUG

Re-modelling Drug Delivery Services for High-viscosity Formulations

Biologic formulations for subcutaneous delivery allow patients to self-administer their treatment and reduce the need for them to consult hospital-based healthcare practitioners. Intravenous formulations are therefore being reformulated for subcutaneous injection (where possible) to capitalise on these benefits. George I’ons at Owen Mumford Pharmaceutical Services outlines the new challenges for the medical device industry and why drug delivery device design must be reconsidered to cater to these new biologics and their requirements.